Zydus Lifesciences bags USFDA final approval for Lenalidomide Capsules; stock under pressure

13 Sep 2022 , 12:32 PM

Zydus Lifesciences Limited informed that it has received the final USFDA approval to market Lenalidomide Capsules, USP 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg.

The company has received final approvals for 5 mg, 10 mg, 15 mg, and 25 mg strengths and tentative approvals for 2.5 mg and 20 mg strength.
Lenalidomide is a cancer treatment medication. It functions by slowing or preventing cancer cell proliferation. It’s also used to treat anemia in those with blood/bone marrow abnormalities.  The company will manufacture the medicine at the group’s formulation manufacturing plant in Ahmedabad Special Economic Zone, India.

According to IQVIA MAT July 2022, lenalidomide had yearly sales of USD 2.86 billion in the United States. The product would be released in the United States soon. The group already has 322 approvals and has filed over 4 applications.

At around 12.57 PM, Zydus Lifesciences was trading at Rs374.70 down by 0.49% from its previous closing of Rs376.55 on the BSE. The scrip touched intraday high and low of Rs379.25 and Rs374.40 respectively.

For feedback and suggestions, write to us at [e-mail]